GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Corona Remedies Ltd
Corona Remedies Board Meeting to Approve Q1 FY27 Unaudited Financial Results
RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 17 Jul 2026, 05:36 PM IST  ·  BSE ID: 2bfd03d6-0eb6-41a1-b32c-7934373cc392
View Original BSE Filing (PDF)
💡
In Simple Terms
Corona Remedies will hold a board meeting on July 31, 2026, to review and approve its financial results for April-June 2026.
🤖 AI Summary
  • Board of Directors meeting scheduled by Corona Remedies Ltd for Friday, July 31, 2026.
  • Agenda includes considering and approving Unaudited Financial Results for Q1 and three months ended June 30, 2026.
  • Results to be approved for both Standalone and Consolidated financial statements.
  • Trading window for company securities remains closed until Sunday, August 02, 2026.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this intimation.
👤
Who Is Affected
Shareholders are indirectly affected as the upcoming financial results will provide updated performance metrics for the company. All shareholders will receive access to the Q1 FY27 results upon their approval and release.
🔍
Management Signal
The scheduling of the board meeting indicates management's adherence to regulatory timelines for quarterly financial disclosures.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Corona Remedies Q1 FY27 financial results — review approved Standalone and Consolidated figures.
Disclosure of any other business discussed and approved during the July 31, 2026 Board Meeting.
Reopening of the trading window after August 02, 2026.
LOW RISK This is a routine procedural announcement regarding an upcoming board meeting.
💡 Investor Takeaway
Corona Remedies Ltd has scheduled a Board Meeting on July 31, 2026, to consider and approve its Unaudited Standalone and Consolidated Financial Results for the first quarter and three months ended June 30, 2026. The trading window remains closed until August 02, 2026.
📅 Company Track Record
Corona Remedies previously reported FY26 revenue up 17.3% to ₹1,403.2 Cr and PAT up 33.4% on May 11, 2026, and recommended a ₹10 final dividend per equity share for FY26.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
When is Corona Remedies Ltd's next Board of Directors meeting?
The next Board of Directors meeting for Corona Remedies Ltd is scheduled for Friday, July 31, 2026.
What is the main agenda for Corona Remedies Ltd's Board Meeting on July 31, 2026?
The main agenda for the Board Meeting on July 31, 2026, is to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the first quarter and three months ended June 30, 2026.
When will the trading window for Corona Remedies Ltd securities reopen?
The trading window for dealing in the securities of Corona Remedies Ltd will remain closed until Sunday, August 02, 2026.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.